2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Stage IIIb and IV Non Small Cell Lung Cancer
1
Solid Tumor, Adult
1
Rare Diseases
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Microsatellite Instability
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Genetic Predisposition to Disease
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Medullary
1
COVID-19
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT02339805
2017-07-07
LymphoSeq
Centre Henri Becquerel
Phase NA
Completed
30 enrolled